Are you prepared for the domino effects of today’s highly networked launch environment? In an ever more interconnected and globalised pharmaceutical universe, there is a strong likelihood the launch of a new product will have significant reverberations beyond national borders. That is why 360˚ visibility of all associated activities from market to market is an indispensable component of launch readiness.

When a new drug comes to market, chances are it will launch globally, or at least across multiple territories. It’s a global marketplace, and with all the restraints on pharmaceutical growth these days, you’ll want to spread your bets. Your launch team needs to be organised globally too.

A pharmaceutical new product launch demands a high level of collaboration by a cross-functional team in what is often a siloed and geographically dispersed business.

Pharmaceutical companies have more reasons than ever to hone their launch readiness skills. The question is whether they possess the new product launch strategies and tools to successfully commercialise their new medicines in an often volatile and always competitive global marketplace.  

As we inch warily or rush enthusiastically into another year against a backdrop of political turmoil and business uncertainty in major markets, it is time to look at the prevailing 2019 pharmaceutical industry trends and what they might mean for companies launching new medicines, negotiating market access barriers, or simply trying to do what they do better. Inevitably, the US is in the thick of the action. But there are many other important 2019 pharma trends, both national and global, that will set the pace for industry throughout what promises to be another dynamic and challenging year.